With many potential new therapies currently in clinical trials, our goal is to be the industry leader in specialty care. We remain focused on discovering scientific breakthroughs to address complex, debilitating diseases.
Explore highlights of our research and development pipeline across our five areas of focus.
Items marked with ^ are being developed in collaboration with Regeneron, * are being developed in collaboration with Alnylam®, and ♦ are being developed in collaboration with Principia Biopharma Inc. Items shown with a † denote a Phase 2/3 trial. Items shown with ▼ denote the INN in the US is cemiplimab-rwlc.
Product Candidate | Technology | Phase I | Phase II | Phase III | Current Phase |
---|---|---|---|---|---|
Immunology |
|||||
Dupilumab^ Nasal Polyposis |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Atopic Dermatitis (12-17 years old) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Atopic Dermatitis (6-11 years old) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Atopic Dermatitis (6 mo - 5 years old) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Asthma (6-11 years old) |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Dupilumab^ Eosinophilic Esophagitis |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Dupilumab^ Grass Immunotherapy |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Dupilumab^ + AR101-CODIT Peanut Allergy - Pediatric |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Sarilumab^ Giant Cell Arteritis |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Sarilumab^ Polymyalgia Rheumatica |
mAb | ![]() |
![]() |
![]() |
PHASE III |
SAR440340^ Asthma |
mAb | ![]() |
![]() |
![]() |
PHASE II |
SAR440340^ COPD |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Sarilumab^ Polyarticular Juvenile Idiopathic Arthritis |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Sarilumab^ Systemic Juvenile Arthritis |
mAb | ![]() |
![]() |
![]() |
PHASE II |
SAR156579^ Systemic Scleroderma |
mAb | ![]() |
![]() |
![]() |
PHASE II |
SAR439794^ Peanut Allergy |
mAb | ![]() |
![]() |
![]() |
PHASE I |
Oncology |
|||||
Isatuximab Relapsing Refractory Multiple Myeloma (IKEMA) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Isatuximab Newly Diagnosed Multiple Myeloma |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Isatuximab 1L Newly Diagnosed Multiple Myeloma (IMROZ) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Cemiplimab^▼ 1L Non-small Cell Lung Cancer |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Cemiplimab^▼ 2L Cervical Cancer |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Cemiplimab^▼ + Ipilimumab 1L Non-small Cell Lung Cancer |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Cemiplimab^▼ Advanced BCC |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Cemiplimab^▼ 2L Non-small Cell Lung Cancer |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Isatuximab + Cemiplimab^▼ Relapsing Refractory Multiple Myeloma |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Isatuximab + Cemiplimab^▼ Advanced Malignancies |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Isatuximab + atezolizumab Advanced Malignancies |
mAb | ![]() |
![]() |
![]() |
PHASE II |
SAR439459 (TGFβ) Advanced Solid Tumors |
mAb | ![]() |
![]() |
![]() |
PHASE I |
SAR408701 (CEACAM5) Solid tumors |
mAb | ![]() |
![]() |
![]() |
PHASE I |
Rare Diseases |
|||||
Fitusiran* Hemophilia A & B |
RNAi | ![]() |
![]() |
![]() |
PHASE III |
Avalglucosidase alfa Pompe disease |
protein-based therapy | ![]() |
![]() |
![]() |
PHASE III |
Venglustat Autosomal Dominant Polycystic Kidney Disease |
small molecule | ![]() |
![]() |
![]() |
PHASE III |
Eliglustat Gaucher Type 1, switch from ERT - Pediatric |
small molecule | ![]() |
![]() |
![]() |
PHASE III |
Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) |
protein-based therapy | ![]() |
![]() |
![]() |
PHASE II |
Venglustat Fabry disease |
small molecule | ![]() |
![]() |
![]() |
PHASE II |
SAR339375 Alport Syndrome |
RNAi | ![]() |
![]() |
![]() |
PHASE II |
Venglustat Parkinson's disease with a GBA mutation |
small molecule | ![]() |
![]() |
![]() |
PHASE II |
Venglustat Gaucher Type 3 |
small molecule | ![]() |
![]() |
![]() |
PHASE II |
Multiple Sclerosis |
|||||
SAR442168♦ Multiple Sclerosis |
BTK inhibitor | ![]() |
![]() |
![]() |
PHASE I |
The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.
In addition to the candidates in clinical development, we are conducting earlier stage research in a range of therapeutic areas including genetic diseases such as cystic fibrosis, spinal muscular atrophy, and Lebers congenital amaurosis type 1. We have several programs in multiple sclerosis with molecules addressing areas of unmet need, using approaches such as immunomodulation, neuroprotection, and remylination.

Avalglucosidase alfa clinical trial
